Literature DB >> 26668318

A Disintegrin and Metalloproteinase with Thrombospondin Motifs-5 (ADAMTS-5) Forms Catalytically Active Oligomers.

Hansen J Kosasih1, Karena Last1, Fraser M Rogerson1, Suzanne B Golub1, Stephanie J Gauci2, Vincenzo C Russo2, Heather Stanton1, Richard Wilson3, Shireen R Lamande2, Paul Holden4, Amanda J Fosang5.   

Abstract

The metalloproteinase ADAMTS-5 (A disintegrin and metalloproteinase with thrombospondin motifs) degrades aggrecan, a proteoglycan essential for cartilage structure and function. ADAMTS-5 is the major aggrecanase in mouse cartilage, and is also likely to be the major aggrecanase in humans. ADAMTS-5 is a multidomain enzyme, but the function of the C-terminal ancillary domains is poorly understood. We show that mutant ADAMTS-5 lacking the catalytic domain, but with a full suite of ancillary domains inhibits wild type ADAMTS activity, in vitro and in vivo, in a dominant-negative manner. The data suggest that mutant ADAMTS-5 binds to wild type ADAMTS-5; thus we tested the hypothesis that ADAMTS-5 associates to form oligomers. Co-elution, competition, and in situ PLA experiments using full-length and truncated recombinant ADAMTS-5 confirmed that ADAMTS-5 molecules interact, and showed that the catalytic and disintegrin-like domains support these intermolecular interactions. Cross-linking experiments revealed that recombinant ADAMTS-5 formed large, reduction-sensitive oligomers with a nominal molecular mass of ∼ 400 kDa. The oligomers were unimolecular and proteolytically active. ADAMTS-5 truncates comprising the disintegrin and/or catalytic domains were able to competitively block full-length ADAMTS-5-mediated aggrecan cleavage, measured by production of the G1-EGE(373) neoepitope. These results show that ADAMTS-5 oligomerization is required for full aggrecanase activity, and they provide evidence that blocking oligomerization inhibits ADAMTS-5 activity. The data identify the surface provided by the catalytic and disintegrin-like domains of ADAMTS-5 as a legitimate target for the design of aggrecanase inhibitors.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ADAMTS; ADAMTS5; aggrecan; cartilage; cartilage biology; metalloprotease; oligomer; oligomerization

Mesh:

Substances:

Year:  2015        PMID: 26668318      PMCID: PMC4751368          DOI: 10.1074/jbc.M115.704817

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing.

Authors:  Masahide Kashiwagi; Jan J Enghild; Christi Gendron; Clare Hughes; Bruce Caterson; Yoshifumi Itoh; Hideaki Nagase
Journal:  J Biol Chem       Date:  2003-12-08       Impact factor: 5.157

2.  A statistical model for identifying proteins by tandem mass spectrometry.

Authors:  Alexey I Nesvizhskii; Andrew Keller; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2003-09-01       Impact factor: 6.986

3.  Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1.

Authors:  M W Olson; M M Bernardo; M Pietila; D C Gervasi; M Toth; L P Kotra; I Massova; S Mobashery; R Fridman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

4.  Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation.

Authors:  Gui Gao; Jennifer Westling; Vivian P Thompson; Troy D Howell; Paul E Gottschall; John D Sandy
Journal:  J Biol Chem       Date:  2002-01-16       Impact factor: 5.157

5.  Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage.

Authors:  Anne-Marie Malfait; Rui-Qin Liu; Kosei Ijiri; Setsuro Komiya; Micky D Tortorella
Journal:  J Biol Chem       Date:  2002-04-15       Impact factor: 5.157

6.  Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo.

Authors:  J D Sandy; C Verscharen
Journal:  Biochem J       Date:  2001-09-15       Impact factor: 3.857

7.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.

Authors:  K Fujikawa; H Suzuki; B McMullen; D Chung
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.

Authors:  J Larkin; T A Lohr; L Elefante; J Shearin; R Matico; J-L Su; Y Xue; F Liu; C Genell; R E Miller; P B Tran; A-M Malfait; C C Maier; C J Matheny
Journal:  Osteoarthritis Cartilage       Date:  2015-03-20       Impact factor: 6.576

9.  Structural basis of the adaptive molecular recognition by MMP9.

Authors:  Hyunju Cha; Erhard Kopetzki; Robert Huber; Martin Lanzendörfer; Hans Brandstetter
Journal:  J Mol Biol       Date:  2002-07-26       Impact factor: 5.469

10.  Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites.

Authors:  Carl R Flannery; Weilan Zeng; Chris Corcoran; Lisa A Collins-Racie; Priya S Chockalingam; Tracy Hebert; Stewart A Mackie; Thomas McDonagh; Tara K Crawford; Kathy N Tomkinson; Edward R LaVallie; Elisabeth A Morris
Journal:  J Biol Chem       Date:  2002-08-28       Impact factor: 5.157

View more
  7 in total

1.  A Numerical Approach for Kinetic Analysis of the Nonexponential Thermoinactivation Process of Uricase.

Authors:  Jing Wu; Xiaolan Yang; Deqiang Wang; Xiaolei Hu; Juan Liao; JingJing Rao; Jun Pu; Chang-Guo Zhan; Fei Liao
Journal:  Protein J       Date:  2016-08       Impact factor: 2.371

Review 2.  ADAMTS-5: A difficult teenager turning 20.

Authors:  Salvatore Santamaria
Journal:  Int J Exp Pathol       Date:  2020-03-27       Impact factor: 1.925

3.  ADAMTS-10 and -6 differentially regulate cell-cell junctions and focal adhesions.

Authors:  Stuart A Cain; Ewa J Mularczyk; Mukti Singh; Teresa Massam-Wu; Cay M Kielty
Journal:  Sci Rep       Date:  2016-10-25       Impact factor: 4.379

4.  Interaction with macrophages attenuates equine fibroblast-like synoviocyte ADAMTS5 (aggrecanase-2) gene expression following inflammatory stimulation.

Authors:  Rhiannon E Morgan; Peter D Clegg; John A Hunt; John F Innes; Simon R Tew
Journal:  J Orthop Res       Date:  2018-03-09       Impact factor: 3.494

5.  ADAMTS-9 in Mouse Cartilage Has Aggrecanase Activity That Is Distinct from ADAMTS-4 and ADAMTS-5.

Authors:  Fraser M Rogerson; Karena Last; Suzanne B Golub; Stephanie J Gauci; Heather Stanton; Katrina M Bell; Amanda J Fosang
Journal:  Int J Mol Sci       Date:  2019-01-29       Impact factor: 5.923

Review 6.  ADAM and ADAMTS Family Proteins and Snake Venom Metalloproteinases: A Structural Overview.

Authors:  Soichi Takeda
Journal:  Toxins (Basel)       Date:  2016-05-17       Impact factor: 4.546

7.  Treatment of Dystrophic mdx Mice with an ADAMTS-5 Specific Monoclonal Antibody Increases the Ex Vivo Strength of Isolated Fast Twitch Hindlimb Muscles.

Authors:  Alex B Addinsall; Leonard G Forgan; Natasha L McRae; Rhys W Kelly; Penny L McDonald; Bryony McNeill; Daniel R McCulloch; Nicole Stupka
Journal:  Biomolecules       Date:  2020-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.